Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of 20-valent Pneumococcal Conjugate Vaccine in Healthy Adults
NCT02955160Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2016
- Primary completion
- Aug 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Prevnar 20 in pneumococcal infection (2 arms), sponsored by Pfizer. Primary endpoints: Percentage of subjects reporting prompted local reactions at Day 15, Percentage of subjects reporting prompted systemic events at Day 15 and 3 more. Started Nov 2016; status: completed.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02955160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955160.